Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
| ▸ | DHFR | P00374 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28876978 | 0.87 | DHFR (0.61) | DHFR | |
| SCHEMBL28907303 | 0.76 | TSHR (0.49) | TSHRCYP19A1 | |
| SCHEMBL30041153 | 0.76 | TSHR (0.49) | TSHRCYP19A1 | |
| SCHEMBL31662914 | 0.76 | DHFR (0.49) | DHFR | |
| SCHEMBL27697197 | 0.75 | CYP19A1 (0.49) | TSHRCYP19A1 | |
| SCHEMBL11801017 | 0.73 | TSHR (0.54) | TSHRCYP19A1 | |
| SCHEMBL10918542 | 0.72 | TSHR (0.71) | TSHRCYP19A1 | |
| SCHEMBL17201936 | 0.72 | EGFR (0.53) | TSHR | |
| SCHEMBL19929612 | 0.71 | KAT2B (0.48) | TSHRDHFR | |
| SCHEMBL21358341 | 0.70 | TSHR (0.48) | TSHRCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | TARGEGEN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, LTK | TSHR 1587/4885CYP19A1 3877/4885DHFR 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.